The Science Board to the Pharmaceuticals and Medical Devices Agency

Tokyo, Japan

The Science Board to the Pharmaceuticals and Medical Devices Agency

Tokyo, Japan
SEARCH FILTERS
Time filter
Source Type

Hayakawa Y.,The Science Board to the Pharmaceuticals and Medical Devices Agency | Hayakawa Y.,University of Toyama | Kawada M.,The Science Board to the Pharmaceuticals and Medical Devices Agency | Kawada M.,Institute of Microbial Chemistry | And 34 more authors.
Cancer Science | Year: 2016

Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. This review summarizes the effective use of animal models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. © 2016 Japanese Cancer Association.

Loading The Science Board to the Pharmaceuticals and Medical Devices Agency collaborators
Loading The Science Board to the Pharmaceuticals and Medical Devices Agency collaborators